LYAG Antibody (G-7): sc-373745

LYAG Antibody (G-7) is a mouse monoclonal IgG1 kappa light chain antibody that detects LYAG protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). LYAG (G-7) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Lysosomal α-glucosidase (LYAG), also known as acid α-glucosidase or acid maltase, plays a critical role in lysosomal degradation of glycogen into glucose, a process vital for maintaining cellular energy homeostasis. LYAG is exclusively located in lysosomes, where LYAG facilitates breakdown of complex carbohydrates, ensuring glucose availability for cellular metabolism. Proper functioning of LYAG is essential, as deficiencies can lead to severe metabolic disorders such as Pompe disease and glycogen storage disease II, both characterized by glycogen accumulation in tissues, particularly affecting muscle function and respiratory health. After translation, LYAG undergoes specific proteolytic processing, resulting in two distinct enzyme forms crucial for activity. Additionally, competitive inhibitor conduritol B epoxide (CBE) can be used to study LYAG function and regulation. With diverse applications and critical role in glycogen metabolism, anti-LYAG antibody (G-7) serves as an invaluable tool for researchers investigating lysosomal function and related metabolic disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LYAG Antibody (G-7) References:

1. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor.  |  Moreland, RJ., et al. 2005. J Biol Chem. 280: 6780-91. PMID: 15520017
2. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.  |  Klinge, L., et al. 2005. Neuromuscul Disord. 15: 24-31. PMID: 15639117
3. Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient with an unusual phenotype.  |  Anneser, JM., et al. 2005. Neurology. 64: 368-70. PMID: 15668445
4. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.  |  Cresawn, KO., et al. 2005. Hum Gene Ther. 16: 68-80. PMID: 15703490
5. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors.  |  Mah, C., et al. 2005. Gene Ther. 12: 1405-9. PMID: 15920463
6. Delayed or late-onset type II glycogenosis with globular inclusions.  |  Sharma, MC., et al. 2005. Acta Neuropathol. 110: 151-7. PMID: 15986226
7. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease.  |  Umapathysivam, K., et al. 2005. Clin Chim Acta. 361: 191-8. PMID: 15993875
8. The natural course of non-classic Pompe's disease; a review of 225 published cases.  |  Winkel, LP., et al. 2005. J Neurol. 252: 875-84. PMID: 16133732
9. Lysosomal enzyme activities: new potential markers for Sjögren's syndrome.  |  Sohar, N., et al. 2005. Clin Biochem. 38: 1120-6. PMID: 16257401
10. Human lysosomal alpha-glucosidase. Characterization of the catalytic site.  |  Hermans, MM., et al. 1991. J Biol Chem. 266: 13507-12. PMID: 1856189
11. Carnitine is a pharmacological allosteric chaperone of the human lysosomal α-glucosidase.  |  Iacono, R., et al. 2021. J Enzyme Inhib Med Chem. 36: 2068-2079. PMID: 34565280
12. 1,6-epi-Cyclophellitol Cyclosulfamidate Is a Bona Fide Lysosomal α-Glucosidase Stabilizer for the Treatment of Pompe Disease.  |  Kok, K., et al. 2022. J Am Chem Soc. 144: 14819-14827. PMID: 35917590

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-LYAG Antibody (G-7) has 4 citations in a variety of scientific publications.

Primary antibodies like Anti-LYAG Antibody (G-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

LYAG Antibody (G-7) Specifications

Alternate Product Name: LYAG

Product Clone Name: G-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 131-190

Epitope Target: LYAG

Epitope Species: human

Product Reactivity/Detection: precursor and mature LYAG

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 4 citations in various scientific publications

Available Conjugates/Forms for LYAG Antibody (G-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin